Depression Clinical Trial
— REGAVPOfficial title:
Regulation of Arginine-vasopressin (AVP) in Psychiatric Disorders
Verified date | December 2015 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This study aims to develop a method for the assessment of central NMDA receptor functioning in patients with depression and schizophrenia. For this purpose a transitional approach is used based on preclinical studies that show a dose-dependent relationship between the activity of hypothalamic NMDA receptor and plasma AVP response to increasing plasma osmolality. Patients with schizophrenia, depression and healthy controls participated in this study. The Investigators found that in a subgroup of patients with schizophrenia the AVP response was low and that in a subgroup of subjects with depression the AVP response was high compared to healthy controls.
Status | Completed |
Enrollment | 25 |
Est. completion date | December 2014 |
Est. primary completion date | November 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion criteria for healthy controls: - Ages of 18-55 years from all ethnic backgrounds. - Male or female. - Smoker or nonsmoker. - Written informed consent. Exclusion criteria for healthy controls: - DSM-IV diagnosis of psychotic, anxiety, mood disorder. - History of major psychiatric disorder in first-degree relatives. - A history of significant medical/neurological disease. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, uric acid, creatinine clearance, LFTs, TFTs, UA, Utox, Urine pregnancy test). - A history of cardiac disease including arrhythmias; history of syncope or unexplained loss of consciousness; history of renal stones or renal failure; history of diabetes mellitus or diabetes insipidus. - Subjects with hypertension (BP > 140/90). - Current hyponatremia. - Serum Ca2+ and uric acid levels that are above normal range. - Serum creatinine outside of normal range for age. - Creatinine clearance <70 ml/min using the Cockcroft-Gault equation (Cockcroft et al 1976) [(140-age)*(weight in kg)*(.85 if female)/(72*Cr)]. - Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures, such as diuretics of any type, lithium, carbamazepine. - Current substance abuse/dependency determined by urine toxicology. - Current treatment with medications with psychotropic effects. - Current pregnancy, unsatisfactory birth control method report for females. - IQ < 70 as determined by Wechsler Abbreviated Scale of Intelligence. - Non-English speaking. Inclusion criteria for patients with schizophrenia: - Ages of 21-55 years from all ethnic backgrounds. - Male or female. - Smoker or nonsmoker. - Written informed consent. - DSM-IV diagnosis of schizophrenia or schizoaffective disorder. - For treated patients: The patient has been on a stable dose of antipsychotics for the past month and does not require a change of medications or dose adjustment at study entry. - For untreated patients: Has refused to be treated with medications, maintains regular clinic appointments with the clinicians, and does not pose an imminent danger to himself or others. Exclusion criteria for patients with schizophrenia - A history of significant medical/neurological disease. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, uric acid, creatinine clearance, LFTs, TFTs, UA, Utox, Urine pregnancy test). - A history of cardiac disease including arrhythmias; history of syncope or unexplained loss of consciousness; history of renal stones or renal failure; history of diabetes mellitus or diabetes insipidus. - Serum Ca2+ and uric acid levels that are above normal range. - Serum creatinine outside of normal range for age. - Creatinine clearance <70 ml/min using the Cockcroft-Gault equation [(140-age)*(weight in kg)*(.85 if female)/(72*Cr)]. - Subjects with hypertension (BP > 140/90). - Current hyponatremia. - Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures, such as diuretics of any type, lithium, carbamazepine. - Currently on clozapine as clozapine may interfere with brain water regulation (Leadbetter and Shutty, 1994). - Current substance abuse/dependency determined by urine toxicology. - Current pregnancy, unsatisfactory birth control method report for females. - IQ < 70 as determined by Wechsler Abbreviated Scale of Intelligence. - Non-English speaking. Inclusion criteria for patients with depression: - Ages of 21-55 years from all ethnic backgrounds. - Male or female. - Smoker or nonsmoker. - Written informed consent. - DSM-IV diagnosis of major depressive disorder, unipolar. - For treated patients: The patient has been on a stable dose of medications (antidepressants) for the past month and does not require a change of medications or dose adjustment at study entry. - For untreated patients: Has refused to be treated with medications, maintains regular clinic appointments with the clinicians, and does not pose an imminent danger to himself or others. Exclusion criteria for patients with depression: - A history of significant medical/neurological disease. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, uric acid, creatinine clearance, LFTs, TFTs, UA, Utox, Urine pregnancy test). - A history of cardiac disease including arrhythmias; history of syncope or unexplained loss of consciousness; history of renal stones or renal failure; history of diabetes mellitus or diabetes insipidus. - Serum Ca2+ and uric acid levels that are above normal range. - Serum creatinine outside of normal range for age. - Creatinine clearance <70 ml/min using the Cockcroft-Gault equation [(140-age)*(weight in kg)*(.85 if female)/(72*Cr)]. - Subjects with hypertension (BP > 140/90). - Current hyponatremia. - Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures, such as diuretics of any type, lithium, carbamazepine. - Current substance abuse/dependency determined by urine toxicology. - Current pregnancy, unsatisfactory birth control method report for females. - IQ < 70 as determined by Wechsler Abbreviated Scale of Intelligence. - Non-English speaking. Inclusion criteria for patients from the PRIME Clinic: - Ages of 18-40 years from all ethnic backgrounds. - Male or female. - Smoker or nonsmoker. - Written informed consent. Exclusion criteria for patients from the PRIME Clinic: - A history of significant medical/neurological disease. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, uric acid, creatinine clearance, LFTs, TFTs, UA, Utox, Urine pregnancy test). - A history of cardiac disease including arrhythmias; history of syncope or unexplained loss of consciousness; history of renal stones or renal failure; history of diabetes mellitus or diabetes insipidus. - Serum Ca2+ and uric acid levels that are above normal range. - Serum creatinine outside of normal range for age. - Creatinine clearance <70 ml/min using the Cockcroft-Gault equation [(140-age)*(weight in kg)*(.85 if female)/(72*Cr)]. - Subjects with hypertension (BP > 140/90). - Current hyponatremia. - Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures, such as diuretics of any type, lithium, carbamazepine. - Currently on clozapine as clozapine may interfere with brain water regulation (Leadbetter and Shutty, 1994). - Current substance abuse/dependency determined by urine toxicology. - Current pregnancy, unsatisfactory birth control method report for females. - IQ < 70 as determined by Wechsler Abbreviated Scale of Intelligence. - Non-English speaking. |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | The John Pierce Laboratory | New Haven | Connecticut |
United States | VA Connecticut Healthcare System | West Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | The John B. Pierce Laboratory, VA Connecticut Healthcare System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AVP response to plasma osmolality as measured by slopes between the two variables | Within 3 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |